Treatment with the diabetes drug pioglitazone for more than 1 year may increase the risk of bladder cancer, the Food and Drug Administration announced in a safety communication issued on June 15. A review of the 5-year data from an ongoing 10-year epidemiologic study of almost 200,000 patients with type 2 diabetes in the Kaiser Permanente Northern California health plan found that overall, there was no increased risk of bladder cancer among the patients who were treated with pioglitazone, compared...